This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Understanding value investing principles is crucial for success. Get clear explanations to strengthen your investment knowledge.
20,239 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Inflation can squeeze many businesses, but some companies thrive by design. This article makes the case for Visa as t...
Insiders are loading up Arbor Realty Trust while bears keep a large short position. The clash over who’s right Arbor ...
Gold prices slide as liquidity fades and risk appetite shifts, forcing traders to rethink the king of safe havens and...
Missouri Sen. Josh Hawley has launched a formal inquiry into FICO’s pricing of mortgage credit scores, seeking FTC sc...
OpenAI is shutting down its Sora video app after a brief six-month run, a move that could reshape consumer AI tools a...
Money moments can feel forced and awkward—whether inflation, debt, or family pressure. This guide turns that discomfo...
Unpack GEO Group's Q1 2026 earnings through the transcript lens. Learn what drove revenue, how margins held up, and w...
This comprehensive guide breaks down Exzeo’s Q1 2026 results, reveals the drivers behind exzeo (xzo) 2026 earnings, a...
Teads released its Q1 2026 results, showing resilience in a volatile ad market. This investor-focused guide breaks do...
With Trump heading to China for high-stakes talks, Goldman Sachs flags a dollar overvaluation of roughly 12-15% versu...
As May 14 approaches, investors weigh growth momentum, profitability, and AI competition around figma's next earnings...